PSMAfore Patient Summary
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)
The purpose of this study is to determine whether Lutetium Lu 177 vipivotide tetraxetan (PluvictoTM) improves the radiographic progression free survival (rPFS) or death compared to a change in androgen receptor-directed therapy (ARDT) in metastatic castration resistant prostate cancer (mCRPC) men that were previously treated with an alternate ARDT but did not receive a taxane-containing therapy for the treatment of CRPC or mHSPC.
What is the Purpose?
The clinical trial objective is to determine whether treatment with PluvictoTM will slow or stop the progression prostate cancer in men with progressive PSMA-positive mCRPC compared to participants treated with ARDT.
What type of therapy is used?
PluvictoTM is the first FDA approved radioligand therapy, which is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle). After administration into the bloodstream, PluvictoTM binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein1. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells disrupting their ability to replicate and/or triggering cell death1.
Who can participate?
Possible patient benefits:
Possible patient risks:
Clinical Trial Site:
Trial sites can be found here
If you are interested in this trial, review the following:
Register your interest or comments about this trial with PHEN
PHEN Contact: 617-481-4020
1.PluvictoTM [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2022.